BCI Pharma – FLT3 project

Strategy

Platform of Selective, Potent , Novel kinase Inh.

Medicinal chemistry

Innovative Therapy for Cancer, Inflammation, Pain, neuro-inflammation

BCI Pharma, a disruptive techno

Now



Future



Technology 2 Clients/Partnership

Selective FLT3 Series BCI-332

- Cancer = AML
- Neuropathic pain
- Autoimmine disease Psorisasis (Expert opinion, 1685, 2008)

X= Clients

YYYYY= Partners

Short term goals

Start clinical development of our Accute Myeloid Leukemia (AML) new treatment

Identify the best combo to cure AML

Identify clinical candidate for neuropathic pain (NP)

Cure AML with a safe combo

Targeted Therapies Could Revolutionize AML Treatment

Raoul Tibes, M.D., Ph.D. - Mayo Clinic Faculty



Targeted therapies offer fresh hope for AML

Dr Andrew Wei ,Alfred Hospital and Monash University, Melbourne, Australia.

BCI-332 – AML (I)

- Market 1,6 billion
- Combo
- Comp : Midostaurin
- Collaboration: Aukland



AML-US

Estimated New Cases in 2016	19,950
% of All New Cancer Cases	1.2%
Estimated Deaths in 2016	10,430
% of All Cancer Deaths	1.8%



Percent Surviving 5 Years
26.6%
2006–2012

Number of New Cases and Deaths per 100,000: The number of new cases of acute myeloid leukemia was 4.1 per 100,000 men and women per year. The number of deaths was 2.8 per 100,000 men and women per year. These rates are age-adjusted and based on 2009–2013 cases and deaths.

BCI-332 – AML (II)



Elderly patients with AML who have comorbidities may have a poorer tolerance to chemotherapy

Need selective drug = less side effect = BCI Pharma

BCI-332 - NP

- Market 7 billion
- Monotherapy

- Ant Na
- Partnership : to be identified

Our competitors

Compound	Ref Cpds	Company	Selectivity	Clinical stage
Crenolanib	CP-868	*Arog Pharmaceuticals*	FLT3,PDGFR,cKIT	Phase III
Quizartinib	AC-220	Ambit-Daiichi	FLT3,PDGFR, CSFR,cKIT	Phase III
Gilteritinib	ASP2215	Astella	FLT3, Ret, AXL, cKIT	Phase III
Midostaurin	PKC-412	Novartis	FLT3, VEGFR2, cKIT, PDGFR, PKc	Phase III

Selectivity of BCI-332





Midostaurin, phase III

IC(50)nM cancer cell

Compounds	Molm-13	Mv4-11
Crenolanib	2.1	2.5
BCI-332	13.0	56.0
BCI-353	7.5	29.0
BCI-475	0.5	0.8
BCI-476	4.4	19.0
BCI-492	3.6	22.0
BCI-513	1.3	4.0
BCI-518	0.4	0.4
BCI-519	0.5	1.4
BCI-555	1.8	9.3

Very potent drugs below nM

Efficacy of BCI-332 in a subcutaneous mice model of MV4-11cell line



%Inh of tumor grow at
10 or 20mpk, po, QD dosing



JNJ-28312141, BID dosing
Mol Cancer Ther, 8, 3151, 2009
MV-4-11 cell line

Identify the best combo to cure AML

MOLM13



Drug	Target/function	Drug class	sDSS Quizartinib	sDSS BCI-332
Refametinib	MEK1/2 inhibitor	B. Kinase inhibitor	7	8
PF-04691502	PI3K/mTOR inhibitor	B. Kinase inhibitor	7,8	6,9
Pimasertib	MEK1/2 inhibitor	B. Kinase inhibitor	9	11,2

OCI-AML3



Drug	Target/function	Drug class	sDSS Quizartinib	sDSS BCI-332
MK-0752	gamma-secretase/notch inhibitor	X. Other	5,7	6,6
IOX-2	PHD2 inhibitor	E. Differentiating/ epigenetic modifier	8,8	5,4
BMS-777607	Met, Axl, Ron and Tyro3 inhibitor	B. Kinase inhibitor	6	7,2

Timing of AML cure project

Timing/Phase	Q1-Q2 2017	Q3-Q4 2017	Q1-Q2 2018	Q3-Q4 2018
FLT3 Inh.	Regulatory Tox	Regulatory Tox	Phase 1a	
FLT3 combo	Identify the best combo	Drug-Drug interaction		Phase 1b

L i c e n c e

Goal = Propose very potent and clean combo to cure AML

Clinical phase

- Phase 1a
  - End point = safety, tolerability, pharmacokinetic and pharmacodynamic

- Phase 1b
  - Combo in relapsed/refractory patient
  - Or
  - Elderly population with many comorbidities and no further treatment options
    - End point = CR and CRi and overal survival
    - Recommended dose for phase 2

Timing of projects



Our competitive avantages

Thanks

Dominique.surleraux@bci-pharma.com
http://www.bci-pharma.com/

References

- FLT3-autoimmune
  - Expert opinion, 1685, 2008
  - Gastroenterology Research and Practice, 1, 2014.
  - Gut. 2012 August ; 61(8): 1154–1162
  - Gut 2005;54:228–236.
  - Immunol Res (2014) 60:112–126
  - BLOOD,VOLUME 114, NUMBER 4, 835, 2009